Cargando…

Safety of Prolonged Wait Time for Nephrectomy for Clinically Localized Renal Cell Carcinoma

BACKGROUND: There is usually a surgical wait time before nephrectomy for patients with clinically localized renal cell carcinoma, and many factors can influence this preoperative wait time. A relatively prolonged wait time may cause tumor progression. Therefore, we assessed the effect of preoperativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Nienie, Zhao, Fangzheng, Liu, Xiaoxiao, Wei, Wei, Wang, Junqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042291/
https://www.ncbi.nlm.nih.gov/pubmed/33859936
http://dx.doi.org/10.3389/fonc.2021.617383
_version_ 1783678095348203520
author Qi, Nienie
Zhao, Fangzheng
Liu, Xiaoxiao
Wei, Wei
Wang, Junqi
author_facet Qi, Nienie
Zhao, Fangzheng
Liu, Xiaoxiao
Wei, Wei
Wang, Junqi
author_sort Qi, Nienie
collection PubMed
description BACKGROUND: There is usually a surgical wait time before nephrectomy for patients with clinically localized renal cell carcinoma, and many factors can influence this preoperative wait time. A relatively prolonged wait time may cause tumor progression. Therefore, we assessed the effect of preoperative wait time on the prognosis of patients with clinically localized renal cell carcinoma. METHODS: The outcomes of 561 patients with clinically localized renal cell carcinoma who underwent nephrectomy between July 2011 and March 2017 were retrospectively evaluated. According to the wait time before surgery, we divided the patients into three groups: short-wait group (≤ 30 days), intermediate-wait group (> 30 and ≤ 90 days), and long-wait group (>90 days). The clinicopathological characteristics were evaluated, and the survival rates of the three groups were compared. RESULTS: This study included 370 male (66%) and 191(34%) female patients, with a median age of 64 years. There were 520 patients with stage T1 and 41 patients with stage T2 tumors. The median interval between diagnosis and surgery was 21 days. There were no significant differences in age, sex, Eastern Cooperative Oncology Group (ECOG) performance status, body mass index, tumor size, surgical approach, surgical procedure, pathological subtype, tumor stage, tumor grade, and residual tumor among the three groups. Overall survival(OS) and cancer-specific survival (CSS) were comparable; the 5-year OS of the short-, intermediate-, and long-wait time groups were 84.2%, 82.0%, and 89.8%, respectively (P=0.732). The 5-year CSS rates of the short-, intermediate-, and long-wait time groups were 87.1%, 88.9%, and 90.4%, respectively (P=0.896). Multivariate analysis revealed that wait time was not an independent prognostic factor for OS or CSS. CONCLUSION: Prolonged surgical wait time (> 90 days) does not influence survival in patients with clinically localized renal cell carcinoma.
format Online
Article
Text
id pubmed-8042291
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80422912021-04-14 Safety of Prolonged Wait Time for Nephrectomy for Clinically Localized Renal Cell Carcinoma Qi, Nienie Zhao, Fangzheng Liu, Xiaoxiao Wei, Wei Wang, Junqi Front Oncol Oncology BACKGROUND: There is usually a surgical wait time before nephrectomy for patients with clinically localized renal cell carcinoma, and many factors can influence this preoperative wait time. A relatively prolonged wait time may cause tumor progression. Therefore, we assessed the effect of preoperative wait time on the prognosis of patients with clinically localized renal cell carcinoma. METHODS: The outcomes of 561 patients with clinically localized renal cell carcinoma who underwent nephrectomy between July 2011 and March 2017 were retrospectively evaluated. According to the wait time before surgery, we divided the patients into three groups: short-wait group (≤ 30 days), intermediate-wait group (> 30 and ≤ 90 days), and long-wait group (>90 days). The clinicopathological characteristics were evaluated, and the survival rates of the three groups were compared. RESULTS: This study included 370 male (66%) and 191(34%) female patients, with a median age of 64 years. There were 520 patients with stage T1 and 41 patients with stage T2 tumors. The median interval between diagnosis and surgery was 21 days. There were no significant differences in age, sex, Eastern Cooperative Oncology Group (ECOG) performance status, body mass index, tumor size, surgical approach, surgical procedure, pathological subtype, tumor stage, tumor grade, and residual tumor among the three groups. Overall survival(OS) and cancer-specific survival (CSS) were comparable; the 5-year OS of the short-, intermediate-, and long-wait time groups were 84.2%, 82.0%, and 89.8%, respectively (P=0.732). The 5-year CSS rates of the short-, intermediate-, and long-wait time groups were 87.1%, 88.9%, and 90.4%, respectively (P=0.896). Multivariate analysis revealed that wait time was not an independent prognostic factor for OS or CSS. CONCLUSION: Prolonged surgical wait time (> 90 days) does not influence survival in patients with clinically localized renal cell carcinoma. Frontiers Media S.A. 2021-03-30 /pmc/articles/PMC8042291/ /pubmed/33859936 http://dx.doi.org/10.3389/fonc.2021.617383 Text en Copyright © 2021 Qi, Zhao, Liu, Wei and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Qi, Nienie
Zhao, Fangzheng
Liu, Xiaoxiao
Wei, Wei
Wang, Junqi
Safety of Prolonged Wait Time for Nephrectomy for Clinically Localized Renal Cell Carcinoma
title Safety of Prolonged Wait Time for Nephrectomy for Clinically Localized Renal Cell Carcinoma
title_full Safety of Prolonged Wait Time for Nephrectomy for Clinically Localized Renal Cell Carcinoma
title_fullStr Safety of Prolonged Wait Time for Nephrectomy for Clinically Localized Renal Cell Carcinoma
title_full_unstemmed Safety of Prolonged Wait Time for Nephrectomy for Clinically Localized Renal Cell Carcinoma
title_short Safety of Prolonged Wait Time for Nephrectomy for Clinically Localized Renal Cell Carcinoma
title_sort safety of prolonged wait time for nephrectomy for clinically localized renal cell carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042291/
https://www.ncbi.nlm.nih.gov/pubmed/33859936
http://dx.doi.org/10.3389/fonc.2021.617383
work_keys_str_mv AT qinienie safetyofprolongedwaittimefornephrectomyforclinicallylocalizedrenalcellcarcinoma
AT zhaofangzheng safetyofprolongedwaittimefornephrectomyforclinicallylocalizedrenalcellcarcinoma
AT liuxiaoxiao safetyofprolongedwaittimefornephrectomyforclinicallylocalizedrenalcellcarcinoma
AT weiwei safetyofprolongedwaittimefornephrectomyforclinicallylocalizedrenalcellcarcinoma
AT wangjunqi safetyofprolongedwaittimefornephrectomyforclinicallylocalizedrenalcellcarcinoma